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Abstract 
Background: Angiogenesis inhibition is a promising approach for treating metastatic colorectal cancer (mCRC). 
Recent evidences support the seemingly counterintuitive ability of certain antiangiogenic drugs to promote normali-
zation of residual tumor vessels with important clinical implications. Lenalidomide is an oral drug with immune-mod-
ulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its 
effectiveness for solid tumors. The aim of this study was to determine whether lenalidomide can normalize colorectal 
cancer neo-vessels in vivo, thus reducing tumor hypoxia and improving the benefit of chemotherapy.
Methods: We set up a tumorgraft model with NOD/SCID mice implanted with a patient-derived colorectal cancer 
liver metastasis. The mice were treated with oral lenalidomide (50 mg/Kg/day for 28 days), intraperitoneal 5-fluoro-
uracil (5FU) (20 mg/Kg twice weekly for 3 weeks), combination (combo) of lenalidomide and 5FU or irrelevant vehicle. 
We assessed tumor vessel density (CD146), pericyte coverage (NG2; alphaSMA), in vivo perfusion capability of residual 
vessels (lectin distribution essay), hypoxic areas (HP2-100 Hypoxyprobe) and antitumor activity in vivo and in vitro.
Results: Treatment with lenalidomide reduced tumor vessel density (p = 0.0001) and enhanced mature pericyte 
coverage of residual vessels (p = 0.002). Perfusion capability of tumor vessels was enhanced in mice treated with 
lenalidomide compared to controls (p = 0.004). Accordingly, lenalidomide reduced hypoxic tumor areas (p = 0.002) 
and enhanced the antitumor activity of 5FU in vivo. The combo treatment delayed tumor growth (p = 0.01) and sig-
nificantly reduced the Ki67 index (p = 0.0002). Lenalidomide alone did not demonstrate antitumor activity compared 
to untreated controls in vivo or against 4 different mCRC cell lines in vitro.
Conclusions: We provide the first evidence of tumor vessel normalization and hypoxia reduction induced by lena-
lidomide in mCRC in vivo. This effect, seemingly counterintuitive for an antiangiogenic compound, translates into 
indirect antitumor activity thus enhancing the therapeutic index of chemotherapy. Our findings suggest that further 
research should be carried out on synergism between lenalidomide and conventional therapies for treating solid 
tumors that might benefit from tumor vasculature normalization.
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Background
Angiogenesis inhibition has shown promising thera-
peutic activity against metastatic colorectal cancer 
(mCRC). VEGF blockade by the monoclonal antibody 
bevacizumab is currently incorporated in clinical prac-
tice and other compounds with similar activity are 
being explored in clinical trials [1–8]. These approaches 
are based on the idea of starving tumors thus preventing 
or reducing neovasculature formation [9–11]. Recent 
evidences have demonstrated that another promis-
ing, and seemingly counterintuitive, aspect of some 
antiangiogenic compounds is the potential to promote 
the normalization of tumor vessels [12–15], which are 
typically immature and disorganized in tumors [10, 16]. 
This effect may have therapeutic benefit by enhancing 
tumor oxygenation, delivery of therapeutic compounds 
or even immune effector cells [17–19]. Abnormal tumor 
vasculature reduces blood flow into tumor sites, poten-
tially hindering the delivery of chemotherapy drugs 
and thus promoting an aggressive hypoxic microen-
vironment that fuels a vicious circle which results in 
the upregulation of pro-angiogenic factors [20–23]. 
Improved chemotherapy outcome was associated with 
vessel normalization in preclinical tumor models [24–
27]. Assessment of vessel normalization is often based 
on morphologic vessel remodeling with functional 
evidences of mature pericyte-coverage and restored 
perfusion ability with consequent variation in tissue 
oxygenation/hypoxia status [28–30]. Awareness of the 
importance of tumor-vessel normalization could modify 
and enrich the old idea of anti-angiogenic therapy. Fur-
ther research is required to explore the effect of antian-
giogenic compounds on vessel-normalization in settings 
such as mCRC, where antiangiogenesis is considered 
to be a significant clinical approach. Lenalidomide is 
an oral derivative of thalidomide, currently approved 
for treating selected hematologic malignancies such as 
multiple myeloma and 5q- myelodysplastic syndrome 
[31–35]. Although the antitumor mechanism of lena-
lidomide is not yet completely clear, it seems to induce 
angiogenesis inhibition and immunomodulation [36, 
37]. Initial experimental trials are exploring the activ-
ity of lenalidomide in mCRC. These studies are aimed at 
exploiting the immunomodulation property of lenalido-
mide in order to increase the activity of anti-EGFR mAb 
cetuximab [38, 39].
We hypothesized that lenalidomide might exert an 
additional beneficial effect on antiangiogenic and tumor-
vessel normalization activity.
Indeed although it is assumed, tumor-vessel normali-
zation has not yet been effectively explored. We set a 
preclinical mCRC model based on a single patient-
derived tumorgraft model generated from a sample of 
liver CRC metastasis [40, 41]. This model was shown 
to be representative of the original patient’s tumor. It 
helps to retain the actual tumor tissue architecture, thus 
providing a platform for studying issues such as tumor 
neo-vessels and their modulation in  vivo. This model 
was used to explore the antiangiogenic and normaliza-
tion effects of oral lenalidomide on CRC neo-vessels, 
including its potential to improve tumor perfusion, 
oxygenation and the therapeutic index of conventional 
chemotherapy.
Methods
Tumor cell lines
All colorectal cancer cell lines were obtained by means of 
American type culture collection (ATCC). Appropriate 
culture medium [HCT116 and LS513 grown in RPMI-
1640 medium, SKCO-1 grown in DMEM medium, and 
LoVo grown in F-12  K medium; American type culture 
collection (ATCC)] was supplemented with 10  % FBS 
(Sigma), 100 U/mL penicillin and 100 U/mL streptomy-
cin (Sigma) in a humidified 5 % CO2 incubator at 37 °C.
Murine CRC patient‑derived tumorgraft
All animal procedures were approved by the inter-
nal animal research ethical committee and the Ital-
ian Ministry of Health. The metastatic CRC sample 
was obtained by carrying out a liver metastasectomy 
on a patient treated at our center. Before the surgical 
intervention the patient was treated with four courses 
of neo-adjuvant chemotherapy with capecitabine and 
oxaliplatin. The tumor presented the following genetic 
mutations: KRAS (p.G12C), APC (p.K1370*) and TP53 
(p.V173E). The patient provided informed consent 
and the study was conducted according to a proto-
col approved by the institutional review board. Tumor 
material not required for histopathologic analysis was 
collected and placed in medium 199 supplemented 
with 200  U/mL penicillin, 200  μg/mL streptomycin, 
and 100  μg/mL levofloxacin. Each sample was cut into 
25- to 30 mm3 pieces in antibiotic-containing medium; 
some of the pieces were incubated overnight in RNA 
later and then frozen at −80 °C for molecular analyses; 
2 other pieces were coated in Matrigel (BD Biosciences) 
and implanted in 2 different 4- to 6-week-old female 
NOD (nonobese diabetic)/SCID (severe combined 
immunodeficient) mice (Charles River). After mass for-
mation, the tumors were passaged and expanded for 2 
generations until production of a cohort of 32 mice [41, 
42]. Four-week-old NOD/SCID mice with established 
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tumors (average volume 400  mm3) were divided into 
four groups (8 mice per group) and treated with oral 
lenalidomide (kindly provided by Celgene) 50  mg/Kg/
day for 28  days, intraperitoneal 5-Fluorouracile (5FU) 
(20  mg/Kg twice weekly for 3  weeks) from pharmacy 
leftovers, combination of lenalidomide and 5FU (doses 
as previously indicated) or irrelevant vehicle (0.5  % 
carboxymethylcellulose and 0.25  % polyoxyethylene 
sorbitan monooleate (Tween® 80) in sterile water) 
respectively. Lenalidomide was administered to the 
mice via oral gavage at the above indicated dose in an 
aqueous suspension containing 0.5 % carboxymethylcel-
lulose and 0.25 % Tween® 80 at a dose volume of 5 mL/
kg.
Tumor size was evaluated weekly by taking caliper 
measurements and the approximate volume of the mass 
was calculated with the formula  4/3  ×  π(d/2)2  ×  D/2, 
where d is the minor tumor axis and D is the major 
tumor axis. The tumor was fixed overnight in 4 % para-
formaldehyde, dehydrated, paraffin-embedded, sectioned 
(5  μm) and stained with hematoxylin and eosin (H&E.; 
Bio Optica).
The percentage of tumor growth inhibition for 
each arm of treatment was calculated with the 
Eq.  100  −  (T/C  ×  100), where T is the mean relative 
tumor volume (RTV) of the treated tumor and C is the 
mean RTV in the control group at the time of sacrifice.
The individual RTV was defined as Vx/V1, where Vx is 
the volume in mm3 at the end of the experiment and V1 
at the start of treatment.
Immunohistochemistry
Paraffin-embedded or OCT-embedded frozen sam-
ples were cut into 5-μm thick sections. The tissue 
slides were treated according to standard immuno-
fluorescence or immunohistochemistry procedures. 
In short, the slides were permeabilized in 0.1  % Tri-
ton X-100 and 0.3  % Tween 20 (Sigma-Aldrich) in 
TBS, treated for 30  min with 1  % hydrogen peroxide 
to quench endogenous peroxidases in immunohisto-
chemistry experiments, and saturated with 5  % goat 
serum (Sigma-Aldrich) in PBS. The slides were incu-
bated with individual primary antibodies overnight at 
4  °C inside a moist chamber. After rinsing in PBS, a 
secondary antibody was added. Secondary HRP-con-
jugate antibodies (EnVision; DakoCytomation) were 
used for immunohistochemistry and the reaction was 
visualized with DAB chromogen (DakoCytomation 
Liquid DAB Substrate Chromogen System, Dako). The 
tissues were counterstained with Mayer hematoxylin 
(Bio-Optica), mounted on glass slides and visualized 
with a BX-60 microscope (Olympus) equipped with 
a color Qicam Fast 1394-digital CCD camera (12 bit; 
QImaging). For carrying out the immunofluorescence 
experiments, Alexa Fluor secondary antibodies were 
used conjugated with Alexa Fluor 488 or Alexa Fluor 
555 fluorochromes (Invitrogen). Molecular probes 
were used for counterstaining the nuclei with DAPI 
(Invitrogen). The slides were analyzed under a Leica 
DM IRBM microscope. The tissues were stained 
with the following primary antibodies: anti–Ki-67 
(DAKO); Anti-MCAM [CD146] (clone EPR3208, Mil-
lipore); purified rat monoclonal anti-panendothelial 
cell ANTIGEN (Meca32) (550563, clone Meca32, 
1:100, BD Pharmingen); rabbit polyclonal anti-α-SMA 
(AB5694, 1:100, Abcam).
Tumor vasculature quantification
Tumor vasculature was evaluated by immunohistochem-
istry. For each animal, the total vessel area in each tumor 
section was quantified as CD146 positive structures by 
computer assisted analysis employing Image-ProPlus 
6.2 software (Media Cybernetics). The CD146 positive 
surface area occupied by vessels was compared with 
total tissue area. In order to better account for the ele-
vated intratumoral heterogeneity, at least 25 microscopic 
observational fields (MOF) (40× magnification) were 
recorded and analyzed from sections of 5 tumors for each 
experimental condition (40× magnification).
Immunofluorescence analysis for pericyte coverage 
and tumor vessel perfusion
All immunofluorescence images were captured and 
analyzed with a Leica SPIIE confocal laser-scanning 
microscope (Leica Microsystems). Image acquisition 
was performed maintaining the same laser power, gain, 
and offset settings in order to quantify pericyte cover-
age (α-SMA and NG2 markers shown by red and green 
channels, respectively) and at least 16 multiple obser-
vational fields (40× magnification) from sections of 3 
tumors for each experimental condition were recorded 
and analyzed. We drew a region of interest (ROI) close 
to each blood vessel (Meca32, shown by violet chan-
nels) and then quantified the MFI of red/green and 
violet channels using the LAS AF Quantification Tool. 
We then calculated the ratio between red/green and 
violet channels for each ROI. In this way the pericyte 
values were normalized on the vessel area. A similar 
procedure was used for quantifying vascular perfu-
sion by FITC-labeled lectin (Vector laboratories, Inc.) 
shown by the green channel. The mice were injected i.v. 
with 0.05 mg FITC-labeled tomato lectin (Lycopersicon 
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esculentum; Vector Laboratories) and were euthanized 
after 2  min. The lectin distribution was visualized by 
means of fluorescent confocal microscopy. The experi-
ments included at least 16 MOF (40× magnifica-
tion) from sections of 3 tumors for each experimental 
condition.
Tumor hypoxia analysis
The amount of tumor hypoxia was determined 15  min 
after injecting 60  mg/kg pimonidazole hydrochloride 
(HP2-100 Hypoxyprobe Kit-Plus; Natural Pharma-
cia International Inc.) into NOD/SCID mice [43]. The 
formation of pimonidazole adducts was detected by 
immunostaining with Hypoxyprobe-1-Mab1 FITC Ab 
according to the manufacturer’s instructions. Immuno-
fluorescence images were captured and analyzed with a 
Leica SPIIE confocal laser-scanning microscope (Leica 
Microsystems).
Immunostaining with Hypoxyprobe-1-Mab1 FITC 
Ab was quantified in at least 10 multiple observational 
fields (40× magnification) from sections of three tumors 
for each experimental condition. In order to quantify 
hypoxic areas in each image, we drew a Region of Inter-
est (ROI) close to each green area (pimonidazole adducts, 
shown by green channel) and a ROI close to each viable 
tissue area (DAPI, shown by blue channels) and we then 
quantified the area with Image-ProPlus 6.2 software 
(Media Cybernetics). The ratio between the green and 
blue areas was calculated and the values were expressed 
as percentages.
Cell viability assays
Four CRC cell lines (HCT116, LS513, SKCO-1 and LoVo 
cells) were plated at a density of 10 cells/μL in complete 
growth medium and seeded in 96-well plastic culture 
plates (Day 0). On Day 1, 100 μl of lenalidomide (Celgene) 
(10 μM), 5 FU (10 μM), combination of lenalidomide and 
5FU or irrelevant vehicle were added to the cells. On Day 
3, cell viability was assessed by quantifying the ATP con-
tent by means of a luminescence assay (CellTiter-Glo, 
Promega). All measurements were recorded with a Glo-
Max 96 Microplate Luminometer (Promega). Growth 
inhibition at each drug concentration was normalized to 
vehicle-treated cells.
Statistical analysis
The means and standard errors were calculated as 
appropriate. Three or more groups (tumor samples 
from mice treated with lenalidomide, 5-FU, Combo 
and irrelevant vehicle) were compared with one-way 
ANOVA and post analysis comparisons were carried 
out among each group with Bonferroni post-test analy-
sis. Curves representing tumor growth in mice treated 
with lenalidomide, 5-FU, Combo and vehicle-treated 
controls were compared with two-way ANOVA and 
post analysis comparisons among each group were car-
ried out with Bonferroni post-test analysis. Combo and 
vehicle treated controls were compared with unpaired t 
test. Values < 0.05 were considered statistically signifi-
cant. The results were analyzed with GraphPad Prism5 
software, where the P value has the following mean-
ing: (*) P  ≤  0.05; (**) P  ≤  0.01; (***) P  ≤  0.001; (****) 
P ≤ 0.0001.
Results
Tumor vessel density and pericyte coverage in residual 
tumor vessels
We explored the activity of lenalidomide on tumor neo-
vasculature in a patient-derived tumorgraft model gener-
ated from a single KRAS-mutated CRC liver metastasis, 
propagated in mice. The mice were treated with oral lena-
lidomide, 5FU or nothing for 28 days after which tumor 
vessel density in multiple MOF per tumor was analyzed. 
The mean CD146 expressions were 12 ±  1, 28 ±  4 and 
40 ± 3 % in tumors removed from lenalidomide-treated 
mice (n = 25), 5FU-treated mice and vehicle-treated con-
trols, respectively (p = 0.0001) (Fig. 1a, b).
Pericyte coverage, assessed by expression of pericyte 
markers NG2 and α-SMA, was significantly enhanced 
by lenalidomide on residual tumor vasculature com-
pared with untreated controls or those treated with 5FU, 
p = 0.0002 for NG2 and p = 0.04 for α-SMA respectively 
(One Way Anova analysis). In fact, the mean expressions 
of NG2 and α-SMA, each normalized for the vascular-
ized area, were respectively 2.88 ± 0.4 and 1.27 ± 0.2 in 
tumors explanted for the mice treated with lenalidomide; 
1.77 ± 0.4 and 0.7 ± 0.1 for the mice treated with control 
vehicle, 0.8 ± 0.2 and 1 ± 0.2 for the mice treated with 
5FU (Fig. 2a, b).
Vessel perfusion capability and effect on tumor hypoxia
In order to gain further insight into the normalization 
effect of lenalidomide, we functionally assessed resid-
ual tumor vessels to determine their perfusion capabil-
ity and consequent effect on tumor hypoxia. Treatment 
with lenalidomide significantly enhanced the perfu-
sion capability of residual tumor vessels (p  =  0.004, 
One Way Anova,); in fact, the MFI mean values of 
lectin/MECA32 ratio normalized on the total vessel 
area, indicative of vessels with regular perfusion, were 
0.6 ± 0.1 in tumors explanted from the mice treated with 
lenalidomide and 0.18 ± 0 in the mice treated with 5FU, 
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compared to 0.08 ± 0.0 observed in vehicle-treated con-
trols (p < 0.001) Fig. 3a, b. Improved perfusion by lena-
lidomide was associated with the reduction of tumor 
hypoxic areas (p  =  0.002, comparing all treatment 
groups with one way anova). In fact, the mean extension 
of the hypoxic areas was 8.6 ± 3.8 % in tumors explanted 
from lenalidomide-treated mice compared to 17.8 ± 4 % 
in vehicle-treated controls (p < 0.05) and 17.5 ± 3 % in 
mice treated with 5FU (p < 0.001); (Fig. 3c, d).
Vessel normalization enhances chemotherapy activity
We determined whether the vessel normalization 
induced by lenalidomide could increase the therapeu-
tic index of conventional chemotherapy in  vivo. The 
simultaneous administration of lenalidomide (50  mg/
Kg) with 5-FU (20  mg/Kg) for 4  weeks induced a sig-
nificant delay in tumor growth in CRC xenograft 
recipient mice compared to vehicle-treated controls 
or mice treated with single drug lenalidomide or 5FU 
(P  =  0.01, Fig.  4a). Compared to the vehicle-treated 
controls, the tumor growth inhibition index was 36  % 
in mice treated with 5FU, 20  % in mice treated with 
lenalidomide and 47 % in mice treated with the combi-
nation of lenalidomide-5FU. A pathological review car-
ried out on tumor samples removed at the end of the 
experiment revealed that the lenalidomide-5FU com-
bination restored the histological features of a normal 
colon. The tissue architecture showed physiologic colon 
crypts, with cells organized as a monostratified epithe-
lium exhibiting reduced polymorphism and polarized 
nuclei towards the basal membrane. An example of 
tumor histology following combined lenalidomide-5FU 
treatment is reported in Fig.  4b. The combination of 
lenalidomide and 5FU significantly reduced the tumor 
Ki67 proliferative index (p  =  0.0002, comparing all 
treatment groups by One Way Anova); the mean Ki67 
expression was 10.6 ± 2.5 % in mice treated with drug 
combination, 32.4 ± 2.2 % in mice treated with vehicle 
control, 19.9  ±  1.6  % in mice treated with 5FU alone, 
21.9  ±  4.2  % in mice treated with lenalidomide alone 
(Fig. 5a, b). Such effect was supported by a vessel nor-
malization effect similar to that observed with lena-
lidomide for both structural (vessel density; pericyte 
coverage) and functional aspects (blood perfusion; oxy-
genation) (Fig. 5c).
Statistical significance (t test) of combination treatment 
versus vehicle was reached relatively to CD146 expres-
sion (22  ±  3  %, p  <  0.0001), perfusion capability (MFI 
lectin/MECA32  =  0.4  ±  0.1; p  <  0.0001) and hypoxia 
(hypoxic area 1 ± 0.5 %; p < 0.001).
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Fig. 1 Lenalidomide reduces mCRC vessel density. a Lenalidomide significantly reduced tumor vessel density, assessed by CD146 expression, in 
5 mice with mCRC tumorgraft compared to the controls treated with irrelevant vehicle or 5FU (p = 0.0001). The cumulative values are presented 
as mean ± SEM of MOF, the groups were compared by one-way ANOVA. Post analysis comparisons of each group with the control vehicle was 
performed with Bonferroni post-test analysis (p < 0.05 for 5FU, p < 0.0001 for lenalidomide). b The pictures report representative IHC images of 
CD146 expression in the mice treated with lenalidomide and control vehicle. MOF, microscopic observation fields; (*), P ≤ 0.05; (**), P ≤ 0.01; (***), 
P ≤ 0.001; (****), P ≤ 0.0001
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Lenalidomide is devoid of direct tumoricidal activity
The absence of direct antitumor activity observed with 
lenalidomide in our in  vivo CRC tumorgraft model was 
confirmed in  vitro against 4 different CRC cell lines. 
Treatment with 5FU or combo (lenalidomide-5FU) sig-
nificantly and similarly killed HCT116, SK-CO-1, LS513 
and LOVO CRC cell lines compared to untreated con-
trols or cells treated with lenalidomide only (p < 0.001). A 
summary of cytotoxicity in vitro against all 4 cell lines is 
reported in Fig. 6 a-d.
Discussion
We reported the first evidence that lenalidomide induces 
normalization of tumor neo-vasculature with improved 
tissue oxygenation and potential therapeutic benefit in a 
preclinical in vivo tumorgraft model of mCRC. Lenalido-
mide is currently used for treating selected hematologic 
malignancies but as yet little is known regarding its effec-
tiveness for solid tumors. Our findings were obtained in 
a preclinical tumor xenograft model generated with a 
liver metastasis from a mCRC patient. Even if potentially 
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Fig. 2 Lenalidomide enhances pericyte coverage of residual mCRC vessels. a Lenalidomide significantly enhanced mature pericyte coverage, 
reported as mean fluorescence intensity (MFI) of α-SMA (p = 0.04) and NG-2 (P = 0.0002) co-localized on vessel areas (MECA32), the results were 
compared with one-way ANOVA. The values are presented as mean ± SEM of MOF, 3 mice with mCRC tumorgraft per group were included in 
the experiments. Post analysis comparisons of each group was performed with Bonferroni post-test analysis, resulting in significant p values of 
lenalidomide against vehicle (*p < 0.05, for α-SMA) and against 5FU (***p < 0.001, for NG2) b Representative immunofluorescence picture showing 
co-localization (merge) of NG2 pericyte marker (green) and Meca32 endothelial marker (red) in tumor samples from mice treated with lenalidomide 
and control vehicle. MOF, Microscopic observation fields; (*), P ≤ 0.05; (**), P ≤ 0.01; (***), P ≤ 0.001
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limited by its single-patient origin, tumorgrafts may 
favorable compare with cell line based models for analyz-
ing issues such as maturation and functionality of tumor 
vessels. Possible strengths are related to the preservation 
of tumor-architecture, even acknowledging that tumor 
neo-vessels are mainly murine, and limitation of genetic 
drift [42].
Lenalidomide has recently been explored in the setting 
of mCRC with the aim of exploiting its immunomodu-
lation activity for potentiating the ADCC effect induced 
by cetuximab. Our findings suggest the added value of 
lenalidomide and broaden its potentialities. In particu-
lar our data may further support synergisms with immu-
notherapy approaches, as the functionality of the vessel 
network is essential for improving the tumor homing of 
immune effectors. The conventional angiogenesis inhi-
bition that is expected when treating with lenalidomide 
was confirmed in our model and the hypothesized “nor-
malization” effect was evident on residual vessels within 
tumors.
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Fig. 3 Lenalidomide enhances vessel perfusion capability and decreases tumor hypoxia. a Lenalidomide significantly enhanced the perfusion 
capability of residual tumor vessels reported as MFI of lectin/MECA32 ratio, indicative of vessels with regular perfusion, normalized on total vessel 
area (p = 0.004 obtained with one-way analysis). The experiments included 3 mice with mCRC tumorgraft per group and the values are presented 
as mean ± SEM of MOF. Post analysis comparisons (*) of each group to control vehicle was performed with Bonferroni post-test analysis (p < 0.01 
for lenalidomide). b Representative immunofluorescence picture showing blood perfusion (lectin in green) within residual tumor vessels (Meca32 
violet as endothelial marker) in mice treated with lenalidomide and vehicle control. c Lenalidomide significantly reduced extension of tumor 
hypoxic areas (p = 0.002) obtained with one-way ANOVA analysis (Kruskal–Wallis). The experiments included 3 mice per group. The graph reports 
values (plus mean ± SEM) of each hypoxic area calculated in vital areas of MOF. Post test analysis comparisons of lenalidomide with control vehicle 
(p < 0.05 *) and 5FU (p < 0.001**) was performed with Bonferroni post-test analysis. d Representative immunofluorescence picture showing hypoxic 
areas (hypoxyprobe) in sections of tumors from mice treated with lenalidomide and control vehicle. The nuclei are counterstained with DAPI (blue). 
MOF, Microscopic observation fields; (*), P ≤ 0.05; (**), P ≤ 0.01
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We observed that tumor xenografts treated with lena-
lidomide in association with 5-FU presented a clear 
trend towards the (re)differentiation of single cells and 
global tissue architecture, resembling features of nor-
mal colon epithelium, indirectly supporting the ben-
eficial activity of chemotherapy. Several morphologic or 
molecular parameters may be considered to be indica-
tive of vessel normalization, but ultimately this phe-
nomenon remains a “functional concept” supported by 
the ability to restore physiologic blood flow and tissue 
oxygenation. We showed that lenalidomide significantly 
increased in vivo perfusion capability of residual tumor 
vessels with regular structures and mature pericyte 
coverage.
The aim of this study was not to confirm mechanis-
tic molecular mechanisms underlying the activity of 
lenalidomide as it has already been investigated in pre-
vious studies. Based on preclinical evidence, lenalido-
mide may inhibit VEGF [44, 45], hinder b-FGF-induced 
endothelial cell cord formation in hypoxic conditions 
and/or block VEGF-induced endothelial cell Akt phos-
phorylation, HIF-1α expression and association of the 
adherent junction proteins in endothelial cells [46]. 
Instead we focused on the functional implications of 
this effect. The improvement in tissue oxygenation 
observed is indicative of normalized blood flow, which 
may occur to break the vicious circle between the 
hypoxia-induced factors that promote dysfunctional 
angiogenesis.
A restored vasculature is important for the efficacy 
of therapeutic interventions and enhanced activity of 
chemotherapy with 5-FU was observed. A limitation of 
our model is its derivation from a single patient’s tumors 
and may not be representative of all CRCs. Of course, 
it was not our aim to propose a new therapeutic com-
bination or to demonstrate the known activity of 5-FU 
against mCRC. The activity of 5-FU was explored only 
as an experimental tool to confirm the possible func-
tional implications of lenalidomide-induced vessel nor-
malization. Our results provide proof of concept that 
chemotherapy may indirectly benefit from the activity of 
lenalidomide on tumor vasculature and the same prin-
ciple could be applied to other active drugs in mCRC. 
Moreover, our findings may provide a favorable biological 
platform for immunotherapy interventions [47]. Func-
tional and restored vessel network is essential for the 
activity of either approved anti EGFR mAb [48] or other 
experimental strategies such as novel immune-check-
point modulators and adoptive cell therapies [26, 49–52]. 
Ultimately all these strategies rely on the effective traf-
ficking and homing of immune effectors at tumor sites 
that could consequently benefit from the healthy status 
of tumor vessels. Furthermore, lenalidomide is endowed 
with intrinsic immunomodulatory activity, promoting 
Fig. 4 Vessel normalization by lenalidomide enhances chemotherapy activity. a The combination of lenalidomide and 5FU significantly delayed 
tumor growth. The experiments included 8 mice per group. Curves with mean tumor volume at each week are reported in the graph, the arrow 
indicates the start of treatments. The groups were compared with two-way ANOVA and post analysis comparisons at the end of treatment for each 
group versus control vehicle with Bonferroni post-test analysis. The percentage of tumor growth inhibition for each group of treatment compared 
to untreated controls is reported below the curves. b Representative histologic images (H&E staining) for each group of treatment. Combination of 
lenalidomide-5FU was associated with the restoration of tissue organization resembling physiologic colon structures
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activation of NK and Cytotoxic T cells, potentially fueling 
a positive biological loop.
Conclusions
Our findings provide proof of concept that lena-
lidomide may have indirect, clinically relevant activ-
ity in the challenging setting of mCRC. The observed 
vessel-normalization effect is consistent with the con-
cept of antiangiogenesis as part of a composite thera-
peutic strategy that benefits from reduced yet functional 
tumor vasculature. Our data may be useful for carrying 
out future experimental clinical trials incorporating lena-
lidomide in order to improve the efficacy of treatments 
against mCRC. Further preclinical studies are required 
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Fig. 5 Combination of Lenalidomide-5FU reduced mCRC proliferation index. a The combination of lenalidomide and 5FU significantly reduced 
Ki67 proliferation index in mice with mCRC tumorgraft (N = 6), compared to controls treated with 5FU (N = 5), Lenalidomide (N = 5) or vehicle 
(N = 6) (p = 0.0002 with one-way ANOVA analysis). The post analysis comparisons of each group to control vehicle was performed with Bonfer-
roni post-test analysis (p < 0.001 for combination therapy). b Representative IHC picture of tumor Ki67 expression in each group of treatment. c 
Combination treatment showed effects similar to those observed with lenalidomide for both structural (pericyte coverage) and functional essays 
(blood perfusion). In the figure is reported a representative immunofluorescence picture showing blood perfusion (lectin in green) within residual 
tumor vessels (MECA 32 violet as endothelial marker, α-SMA in red for pericyte coverage) in mice treated with lenalidomide, vehicle control, 5-FU 
and combination treatment (Yellow/white color indicates merging of lectin/MECA32/α-SMA)
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to in order to determine whether the observed activity 
of lenalidomide may be extended to other forms of solid 
tumors and be used in combination with other immuno-
therapy strategies.
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